Aller au contenu
Santé cardiovasculaireEssai randomisé3 min read

Type 2 diabetes with albuminuria: more risk factors off target, more heart events and deaths

Collectif éditorial MoveVitals · Study published · Reading updated

Original paper:The number of risk factors not at target is associated with cardiovascular risk in a type 2 diabetic population with albuminuria in primary cardiovascular prevention. Post-hoc analysis of the NID-2 trial. · Cardiovascular diabetology · 2022 · Article original ↗

À retenir

In people with type 2 diabetes, albuminuria and no prior cardiovascular disease, having all 4 risk factors off target was linked to about twice the hazard of major cardiac events (HR 1.91; 95% CI 1.04-3.52) and death (HR 1.96; 95% CI 1.02-3.8) versus 0-1. This is a post-hoc grouping of a trial, and only 23 people were in the highest-risk group.

Study design

Essai randomisé

Reading basis

Published abstract

Reading focus

Comparator & uncertainty

Cette explication éditoriale existe en anglais, chinois simplifié et chinois traditionnel. Cette interface affiche la lecture en anglais.

Question de recherche

The NID-2 trial earlier showed that multifactorial intensive treatment reduced major adverse cardiac events (MACEs) and death in people with type 2 diabetes and albuminuria. This post-hoc analysis asked whether the number of risk factors that stay off target relates to patient outcomes, regardless of which treatment arm they were in.

Population et méthode

Post-hoc analysis of NID-2, an open-label cluster randomized clinical trial of type 2 diabetes with albuminuria and no history of cardiovascular disease. The intervention phase lasted four years, followed by 10 years of survival follow-up. Participants were divided into 3 groups by number of risk factors off target: 0-1 (absent/low), 2-3 (intermediate) and 4 (high). The primary endpoint was a composite of fatal and non-fatal MACEs; the secondary endpoint was all-cause death. Cox models were adjusted for confounders, including treatment arm. The trial is registered as NCT00535925.

Résultats

The authors’ reported results. Read each estimate with its population and uncertainty.

  1. 1
    Group sizes were 166 patients (52.4%) in the absent/low group, 128 (40.4%) in the intermediate group and 23 (7.3%) in the high-risk group.
  2. 2
    After adjustment including treatment arm, the high-risk group had a higher hazard of MACEs than the absent/low group (HR 1.91, 95% CI 1.04-3.52, P = 0.038).
  3. 3
    The high-risk group also had a higher hazard of all-cause death (HR 1.96, 95% CI 1.02-3.8, P = 0.045). The abstract does not report results for the intermediate group.

Limites et incertitude

  1. 1
    The analysis is post-hoc, so it shows association rather than the effect of reaching targets.
  2. 2
    The high-risk group had only 23 patients, so the hazard ratios have wide confidence intervals with lower limits near 1.
  3. 3
    The abstract does not report results for the intermediate group or the number of events.
  4. 4
    Participants had type 2 diabetes with albuminuria and no prior cardiovascular disease, so results may not apply to other people with diabetes.

Mise en perspective

For people with type 2 diabetes and kidney damage, having several risk factors, such as blood pressure, glucose, lipids and the like, at target went with fewer heart events. The study cannot show how much benefit any single target gives. Treatment targets should be set with your clinician.

Vos données

A home blood pressure cuff, glucose records (finger-stick or CGM), and weight can show how many of your own risk factors are in the range your clinician set. Record them in the same way and at consistent times, and review trends with your clinician rather than reacting to single readings.

Comprendre ce type de preuve

Randomisation can support causal inference, but check allocation, blinding, missing outcomes, follow-up and the actual comparator. A trial label alone does not establish high certainty.

Résumé structuré des auteurs English

Le résumé original en anglais est reproduit avec attribution sous la licence ouverte indiquée. Il s’agit d’une source, pas d’une interprétation MoveVitals. L’analyse préparée figure ci-dessus ; vérifiez les conclusions importantes dans la source.

Background

Nephropathy in Diabetes type 2 (NID-2) study is an open-label cluster randomized clinical trial that demonstrated that multifactorial intensive treatment reduces Major Adverse Cardiac Events (MACEs) and overall mortality versus standard of care in type 2 diabetic subjects with albuminuria and no history of cardiovascular disease. Aim of the present post-hoc analysis of NID- 2 study is to evaluate whether the number of risk factors on target associates with patient outcomes.

Methods

Intervention phase lasted four years and subsequent follow up for survival lasted 10 years. To the aim of this post-hoc analysis, the whole population has been divided into 3 risk groups: 0-1 risk factor (absent/low); 2-3 risk factors (intermediate); 4 risk factors (high). Primary endpoint was a composite of fatal and non-fatal MACEs, the secondary endpoint was all-cause death at the end of the follow-up phase.

Results

Absent/low risk group included 166 patients (52.4%), intermediate risk group 128 (40.4%) and high-risk group 23 (7.3%). Cox model showed a significant higher risk of MACE and death in the high-risk group after adjustment for confounding variables, including treatment arm (HR 1.91, 95% CI 1.04-3.52, P = 0.038 and 1.96, 95%CI 1.02-3.8, P = 0,045, respectively, vs absent/low risk group).

Conclusions

This post-hoc analysis of the NID-2 trial indicates that the increase in the number of risk factors at target correlates with better cardiovascular-free survival in patients with type 2 diabetes at high CV risk.

Clinical trial registration

ClinicalTrials.gov number, NCT00535925. https://clinicaltrials.gov/ct2/show/NCT00535925.

Sources et attribution

The number of risk factors not at target is associated with cardiovascular risk in a type 2 diabetic population with albuminuria in primary cardiovascular prevention. Post-hoc analysis of the NID-2 trial.

Sasso FC, Simeon V, Galiero R, Caturano A, De Nicola L, Chiodini P, Rinaldi L, Salvatore T, Lettieri M, Nevola R, Sardu C, Docimo G, Loffredo G, Marfella R, Adinolfi LE, Minutolo R, NID-2 study group Investigators.

Cardiovascular diabetology · 2022-11-07

DOI: 10.1186/s12933-022-01674-7 ↗PubMed · 36344978 ↗Europe PMC · Licence indiquée: cc by ↗

Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.

Interprétation éditoriale MoveVitals · contenu éducatif · aucune évaluation clinique individuelle enregistrée

Sources vérifiées 2026-11-01

Guides pratiques

À lire ensemble

·Méta-analyse observationnelle

Disrupted daily rest-activity rhythm is linked to higher mortality in 109,365 people

Across seven observational studies with 109,365 participants, a weaker day-night activity contrast (lower relative amplitude) was associated with higher cardiovascular mortality (hazard ratio [HR] 1.50, 95% CI 1.13 to 1.98) and all-cause mortality (HR 1.46, 95% CI 1.27 to 1.68). The evidence base is small and observational, so it cannot show that improving the rhythm lowers risk, and illness may itself disturb the rhythm.

Journal of the American Heart Association

Explications approfondiesLire l’étude →
·Méta-analyse d’essais

Five exercise types lowered resting blood pressure, isometric training the most

Pooling 270 randomised trials with 15,827 participants, aerobic, resistance, combined, interval and isometric training all lowered resting blood pressure compared with non-intervention controls (P<0.001 for each), with the largest fall for isometric training: 8.24 mm Hg systolic and 4.00 mm Hg diastolic. The ranking between modes is partly indirect and the trials differ, so it is not a personal prescription.

British Journal of Sports Medicine

Explications approfondiesLire l’étude →
·Essai randomisé

A salt substitute lowered stroke, major cardiovascular events and death in rural China

In 20,995 people in 600 rural Chinese villages who had a history of stroke or were 60 or older with high blood pressure, a salt substitute (75% sodium chloride, 25% potassium chloride) lowered the stroke rate versus regular salt over a mean 4.74 years: 29.14 versus 33.65 events per 1000 person-years (rate ratio 0.86, 95% CI 0.77 to 0.96; P = 0.006). Death was also lower (rate ratio 0.88) and serious hyperkalemia events were not significantly higher, but the trial was open-label and set in rural China.

The New England Journal of Medicine

Explications approfondiesLire l’étude →
·Validation : étude/revue

Apple Watch irregular-pulse alerts were rare; 34% of those tested had atrial fibrillation

Among 419,297 Apple Watch users with no known atrial fibrillation (AF), 0.52% received an irregular-pulse alert, and 34% of the 450 who returned a usable ECG patch had AF (97.5% CI 29 to 39). Alerts that coincided with patch recording matched AF with a positive predictive value of 0.84 (95% CI 0.76 to 0.92), but only 20.8% of alerted people returned a patch and nobody without an alert was monitored, so a quiet watch does not rule AF out.

The New England Journal of Medicine

Explications approfondiesLire l’étude →
Santé cardiovasculaire →